Skip to content

Cascadian Therapeutics, Inc.

CIK 0001412067

← back to feed
Revenue (TTM)
$145K
+705.6% YoY FY Mar 2018
Net Income (TTM)
−$50.95M
−19.2% YoY FY Mar 2018
EPS Diluted (TTM)
−$0.69
−3.2% YoY FY Mar 2018
Gross Margin
—
FY Mar 2018
Operating Margin
-35,677.9%
FY Mar 2018
Net Margin
-35,134.5%
FY Mar 2018
Free Cash Flow (TTM)
−$33.32M
FY Mar 2018
Cash
$16.78M
FY Mar 2018
Total Debt
—
FY Mar 2018
Shares Outstanding
55.32M sh
FY Mar 2018

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings